Product Images Cleviprex

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 15 images provide visual information about the product associated with Cleviprex NDC 18124-011 by Fresenius Kabi Austria Gmbh, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Clevidipine Structure and Formula - cleviprex figure 1

Clevidipine Structure and Formula - cleviprex figure 1

Package Label - Principal Display Panel - 50mg/100mL Vial Label - cleviprex figure 10

Package Label - Principal Display Panel - 50mg/100mL Vial Label - cleviprex figure 10

Package Label - Principal Display Panel - 50mg/100mL Inner Carton - cleviprex figure 11

Package Label - Principal Display Panel - 50mg/100mL Inner Carton - cleviprex figure 11

Package Label - Principal Display Panel - 50mg/100mL Outer Carton - cleviprex figure 12

Package Label - Principal Display Panel - 50mg/100mL Outer Carton - cleviprex figure 12

This appears to be a label of a medication named Cleviprex. It includes information about the concentration of the medication, the NDC code, and the amount of single-use vials provided. Not enough information is provided to determine the usage and application instructions for this medication.*

Package Label - Principal Display Panel - 125mg/250mL Vial Label - cleviprex figure 13

Package Label - Principal Display Panel - 125mg/250mL Vial Label - cleviprex figure 13

(clevidipine) injectable emulsion with a concentration of 125 mg per 250 mL, equivalent to 0.5 mg/m. The remaining text is not readable and appears to be a mix of numbers, letters, and symbols.*

Package Label - Principal Display Panel - 125mg/250mL Inner Carton - cleviprex figure 14

Package Label - Principal Display Panel - 125mg/250mL Inner Carton - cleviprex figure 14

This is a medication label for Clevidipine Injectable Emulsion. It contains information on dosage and storage instructions. The medication is contraindicated for patients with impaired liver or kidney function and severe aortic stenosis. It must be stored at room temperature and not be frozen. The label warns against contamination and advises on proper disposal after two months of use. Details of proper handling and administration are included. There is also a warning against using the medication beyond two months after opening the container.*

Package Label - Principal Display Panel - 125mg/250mL Outer Carton - cleviprex figure 15

Package Label - Principal Display Panel - 125mg/250mL Outer Carton - cleviprex figure 15

This is a description of a drug named Cleviprex, which is an injectable emulsion of 125 mg / 250 mL (0.5 mg/mL). It comes in single-use vials and is for intravenous use only. This text also provides warnings for storage and handling of the drug.*

Figure 1. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex figure 2

Figure 1. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex figure 2

This is a graph that shows the mean change in systolic blood pressure (in mmHg) from baseline, over time (in minutes). The graph compares the effects of Clevidipine versus a placebo. No further information can be obtained from the given text.*

Figure 2. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex figure 3

Figure 2.  Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex figure 3

The text describes a chart or graph displaying the mean change in systolic blood pressure (in mmHg) from baseline over 30 minutes. The chart also includes data on the number of participants who dropped out during the 30-minute infusion. The x-axis shows time in minutes, with data points at 10, 15, 20, 25, and 30 minutes.*

Figure 3. Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex figure 4

Figure 3.  Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex figure 4

Figure 4. Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex figure 5

Figure 4.  Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex figure 5

Clevidipine is a medication indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. The text seems to be incomplete and does not provide any further descriptive information.*

Figure 5. Mean percent change in SBP (%) during the first 30 minutes of infusion, VELOCITY (severe hypertension) - cleviprex figure 6

Figure 5.  Mean percent change in SBP (%) during the first 30 minutes of infusion, VELOCITY (severe hypertension) - cleviprex figure 6

Package Label - Principal Display Panel - 25mg/50mL Vial Label - cleviprex figure 7

Package Label - Principal Display Panel - 25mg/50mL Vial Label - cleviprex figure 7

Package Label - Principal Display Panel - 25mg/50mL Inner Carton - cleviprex figure 8

Package Label - Principal Display Panel - 25mg/50mL Inner Carton - cleviprex figure 8

This appears to be a mixture of product names, dosage information, and administration instructions for injectable emulsions. The products mentioned are Cleviprex and Clvidipine, both of which are 25mg/50 mL (0.5 mg/mi) injectable emulsions. The text mentions a single-use vial and discarding any unused portion, as well as instructions for administration. Without additional context on the purpose and use of these products, it is difficult to provide a more specific description.*

Package Label - Principal Display Panel - 25mg/50mL Outer Carton - cleviprex figure 9

Package Label - Principal Display Panel - 25mg/50mL Outer Carton - cleviprex figure 9

Description: This appears to be a medication prescription label containing information about two different injectable emulsions with the brand names Viaks and Romy. Each emulsion contains 25mg or 0.5 mg of an active ingredient in a 50mL solution and is intended for single-use, intravenous administration.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.